Eslami M, Mehrabi M, Payandeh M, Saba F, et al. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol. PLoS One 2024;19:e0308247.
PMID: 39088571